AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Tourette Syndrome

Recent research efforts aimed at curing Tourette Syndrome.

Last updated

Tourette Syndrome

Overview

Tourette Syndrome (TS) is a childhood-onset neurodevelopmental condition defined by multiple motor tics (sudden movements) and at least one vocal tic lasting more than a year. Symptoms commonly begin between ages 5 and 10, wax and wane over time, and often lessen during adolescence or early adulthood, although some people continue to have impairing tics as adults. Attention-deficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), anxiety, and other conditions are common and may cause more day-to-day disability than tics themselves. CDC overview

There is no cure for TS. Many people need no tic-specific treatment; when tics cause pain, injury, distress, or problems at school, work, or socially, current care combines education and accommodations, Comprehensive Behavioral Intervention for Tics (CBIT), treatment of co-occurring conditions, and—when needed—medication to reduce tic severity. CBIT teaches awareness of urges and alternative “competing responses”; it helps manage symptoms but is not a cure. CDC treatment guidance

Scope of Recent Research (2020–present)

Research activity since 2020 has been substantial but remains focused mainly on safer symptomatic treatments, better delivery of behavioral therapy, circuit-based neuromodulation, and identifying biological subtypes rather than on reversing a single known cause. Recent trial reviews identify a diverse but relatively small pipeline of dopamine-pathway drugs, cannabinoid-related agents, and neuromodulation approaches. Because TS has complex genetic and developmental causes rather than one established, correctable mutation or missing cell type, no gene therapy, gene-editing, RNA-replacement, or cell-replacement therapy is close to clinical use as a cure. Clinical-trial review

Major Breakthroughs and Emerging Therapies

The clearest recent drug advance is ecopipam, an oral selective dopamine D1-receptor antagonist developed to avoid some limitations of conventional D2-blocking antipsychotic drugs. In a 2023 phase 2b randomized trial in 153 children and adolescents, ecopipam produced a greater 12-week reduction in Yale Global Tic Severity Scale total tic scores than placebo. Phase 2b ecopipam trial A subsequent phase 3 randomized-withdrawal study found that, among participants who first improved during open-label ecopipam treatment, continued ecopipam significantly delayed relapse in pediatric participants: 41.9% relapsed on ecopipam versus 68.1% on placebo during the blinded period. Phase 3 ecopipam trial This is an important treatment-development result, but it demonstrates maintenance of tic control in prior responders—not a permanent cure or prevention of TS.

A second small-molecule strategy is gemlapodect (NOE-105), a phosphodiesterase-10A inhibitor intended to modulate dopamine signaling in basal-ganglia circuits involved in movement control. Noema Pharma’s multicenter ALLEVIA 2 phase 2b trial enrolled adolescents and adults for 12 weeks of gemlapodect or placebo, using tic severity on the Yale scale as its main outcome; the European trial record lists the study as ended on February 12, 2026, but does not provide efficacy results. ALLEVIA 2 trial record This illustrates both the expanding pipeline and its uncertainty: promising mechanisms still require replicated, independently published clinical outcomes. Conversely, the negative 2021 randomized pediatric trial of the dopamine-depleting VMAT2 inhibitor deutetrabenazine found no significant tic-score advantage over placebo, underscoring that a plausible dopamine-targeting mechanism does not necessarily translate into meaningful benefit. Deutetrabenazine trial

Circuit-directed treatments are also advancing. Deep brain stimulation (DBS)—surgically implanted electrodes that continuously modulate selected brain circuits—remains an option only for exceptionally severe, treatment-refractory cases. In a 2021 randomized sham-controlled study, stimulation of the posteroventral internal globus pallidus reduced tics at the group level, whereas thalamic stimulation did not show a significant group-level effect, emphasizing that the best target and patient-selection rules remain unsettled. DBS target-comparison trial Less invasive approaches include rhythmic median-nerve stimulation delivered by a wrist-worn device and transcranial magnetic stimulation (TMS), which uses magnetic pulses outside the skull to alter brain activity. These approaches may reduce tics or urges for some people, but controlled evidence remains preliminary and heterogeneous. Home median-nerve stimulation trial TMS meta-analysis

Behavioral and digital approaches are not biological cures, but they are an important practical research frontier because specialist access is limited. A 2024 follow-up of a 221-participant randomized trial found that therapist-supported internet-delivered exposure and response prevention was not superior to online psychoeducation for tic severity at 12 months, although both groups retained gains and the intervention may be cost-effective in some health-system analyses. Internet-delivered behavioral trial follow-up The priority is therefore not simply to place an existing therapy online, but to determine which patients benefit, how to sustain improvement, and how to deliver expert care equitably.

Clinical Trials and Experimental Approaches

Ecopipam is the most clinically advanced investigational medicine. Its phase 2b pediatric trial was positive, and the phase 3 randomized-withdrawal study confirmed a lower relapse risk among pediatric responders continuing treatment. Phase 2b ecopipam trial Phase 3 ecopipam trial Teva submitted a U.S. New Drug Application for pediatric TS on June 18, 2026; an application is a regulatory request and is not the same as FDA approval. Teva NDA announcement

Gemlapodect’s phase 2b ALLEVIA 2 study is another notable recent program. The study was designed as a randomized, double-blind, placebo-controlled trial of up to 180 adolescents and adults in the United States and Europe; its European record lists it as ended, with no posted results in that record as of September 30, 2026. ALLEVIA 2 trial record Meanwhile, DBS studies continue to compare stimulation targets and settings in carefully selected adults with severe disease, while trials of wearable peripheral-nerve stimulation and noninvasive brain stimulation aim to achieve benefits without brain surgery. DBS target-comparison trial Home median-nerve stimulation trial

Methodologies and Scientific Approaches

TS research increasingly combines large-scale genetics with functional neuroscience. A 2023 genome-wide association meta-analysis of 6,133 people with TS and 13,565 controls identified a genome-wide significant region at chromosome 5q15 and implicated the developmental gene NR2F1 and related noncoding RNA, while also linking polygenic risk with thalamic and putamen brain-volume measures. Such findings can identify pathways and subgroups, but they do not establish a single gene to edit in patients. TS genome-wide association study

Researchers are also building patient-derived models. In 2022, investigators used induced pluripotent stem cells—adult cells reprogrammed into stem-like cells—to create basal-ganglia organoids from people with TS; the organoids showed altered developmental patterning and reduced interneuron-related features. Basal-ganglia organoid study Alongside organoids and animal models, studies use brain imaging, electrophysiology, wearable tic measurement, and blood-based biomarker searches to identify treatment-response markers. A 2024 systematic review found that peripheral biomarker findings remain inconsistent, so no blood test can yet diagnose TS or select a curative therapy. Biomarker systematic review

Leading Institutions and Funding

Cincinnati Children’s Hospital Medical Center and Emalex Biosciences led key ecopipam studies, with Teva advancing the regulatory program after acquiring Emalex. Phase 3 ecopipam trial Karolinska Institutet, Region Stockholm, the University of Nottingham, University College London, and Great Ormond Street Hospital have led major digital behavioral-therapy research. Internet-delivered behavioral trial follow-up Genetics work is driven by multinational consortia integrating TS cohorts and genomic datasets, while DBS research depends on specialized movement-disorder and functional-neurosurgery centers. TS genome-wide association study

The Tourette Association of America (TAA) is a central nonprofit funder and convener: it reports more than $23 million in cumulative research support since 1984 and supports genetics, neuroimaging, behavioral-science, and DBS collaborations. TAA research program Its Young Investigator Award provides up to $75,000 per year for two years, or $150,000 total, for early-career researchers. TAA Young Investigator Award U.S. public support also includes the CDC Tourette Syndrome Research and Education Program, funded at $2.5 million in fiscal year 2025. CDC fiscal year 2025 budget justification

Strengths, Limitations, and Challenges

The field’s strengths are a clearer focus on brain-circuit biology, a growing willingness to run controlled multicenter trials, and the emergence of ecopipam as a non-D2 dopamine strategy with positive phase 2b and phase 3 evidence. Phase 2b ecopipam trial Phase 3 ecopipam trial Digital behavioral interventions and wearable stimulation may also improve access or reduce treatment burden if effectiveness is confirmed. Internet-delivered behavioral trial follow-up Home median-nerve stimulation trial

The central limitation is biological complexity. TS is heterogeneous, developmental, and polygenic; current genetic findings are risk signals rather than singular disease-causing errors that can be repaired with gene editing. TS genome-wide association study Trials are often small, short, and affected by fluctuating symptoms, placebo response, psychiatric comorbidity, and different tic-rating methods. Ecopipam also has safety considerations—including somnolence, insomnia, anxiety, mood symptoms, and rare suicidal ideation in the phase 3 study—that require careful monitoring. Phase 3 ecopipam trial DBS can help selected patients but entails surgery, programming demands, and device-related risk, making it unsuitable as a broadly scalable cure. DBS target-comparison trial

Outlook and Future Directions

As of September 30, 2026, TS is not close to a curative gene, cell, or disease-reversing therapy. The near-term milestone to watch is the FDA review of ecopipam, which could expand symptom-treatment options but would not cure TS. Teva NDA announcement The longer-term path toward a genuine cure will require much larger and more diverse genetic datasets, validated biomarkers that distinguish biological subtypes, developmental human models that reproduce the relevant circuits, and trials that show durable normalization of symptoms after treatment ends—not merely tic reduction while treatment continues. Clinical-trial review Basal-ganglia organoid study

References

Don't see your disease? Request a report